Results of real world clinical practice with anti-VEGF treatments, presented at this year’s American Society of Retina Specialists (ASRS) 2016 Annual Meeting, highlighted a considerable… Read More »Mind the gap – results may differ: conference highlights difference between clinical practice and clinical trials with anti-VEGF therapies
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 18th, 2016: “EURETINA-Brief”© Issue No. 138
GenSight Biologics S.A. (Euronext: SIGHT) has raised over €40M on the Euronext exchange following a venture capital fundraising of €36M approximately 12 months prior. The… Read More »GenSight SA (Paris, France) raises €40M in IPO on Euronext.
A clinical study testing an infusion of mecasermin rinfabate (“iPlex” or “SHP607”), a drug combination of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor… Read More »Clinical trial misses critical end-point in retinopathy of prematurity (ROP) study.
Research conducted by scientists based at the University of California San Diego and the Stanford University School of Medicine has shown that crushed optic nerve… Read More »Regeneration of retinal axons through visual stimulation and gene activation may have clinical potential in treating vision loss
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 1st, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 1st, 2016: “EURETINA-Brief”© Issue No. 137
The decision by the UK electorate on June 23rd to leave the European Union (EU) is likely to have a number of significant consequences for… Read More »Brexit decision is likely to have significant impact on drug development and IP protection.
A US expert panel (the U.S. Preventive Services Task Force, USPSTF) has recommended that it is cost-effective to screen overweight and obese adults between the… Read More »USPSTF expert panel recommends glucose screening for all overweight / obese 40-70 year olds.
Research, led by the Centre for Experimental Medicine, Queen’s University Belfast, has shown that inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) with darapladib, an experimental GSK… Read More »Researchers demonstrate potential benefit from targeting phospholipase A2 in model of diabetic macular edema (DME)
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 6th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »July 6th, 2016: “EURETINA-Brief”© Issue No. 136